NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

Contributed by: PR Newswire

Tags

SOBI

More Like This

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Sobi's strength in haematology to be showcased at ASH 2024

Sobi to present new data at EAHAD 2024

PR Newswire associated0

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Sobi to present new data at ASH 2023 Annual Meeting

PR Newswire associated0

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024